KPTI7:00 AMKaryopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume ReductionTrial Results • Phase 3karyopharm.com